Join our daily newsletter At The Bell to receive exclusive market insights
- Results from Noxopharm’s (NOX) chemotherapy enhancement program have been published in the peer-reviewed “Current Therapeutic Research” journal
- The patients selected for the program had late-stage metastatic solid cancers that had failed previous treatments and were considered unlikely to respond to further chemotherapy
- By the final treatment cycle, 83 per cent of patients treated with Noxopharm’s drug candidate Veyonda had stabilised their disease
- Noxopharm is now in the process of reviewing its clinical programs portfolio for a further study in combination with chemotherapy
- Noxopharm shares are down 1.67 per cent, trading at 59 cents
Results from Noxopharm’s (NOX) chemotherapy enhancement program have been published in the peer-reviewed “Current Therapeutic Research” journal.
The Australian clinical-stage drug development company Noxopharm focusses on the treatment of cancer and septic shock, using its first pipe-line drug candidate, Veyonda.
In 2018, Noxopharm reported that European researchers found Veyonda resulted in a positive outcome in a high proportion of patients, when given in combination with low doses of the widely used chemotherapy drug, carboplatin.
The publication today reported the completed chemotherapy enhancement program (CEP-1) data after being peer-reviewed.
The patients selected for the program had late-stage metastatic solid cancers, like breast, lung, ovarian and prostate, that had failed previous treatments and were considered unlikely to respond to further chemotherapy.
The study demonstrated the majority of patients had stabilised their disease throughout the treatment course.
By the final treatment cycle, 83 per cent of patients treated with 800 milligrams of Veyonda had stable disease or a partial response. One particular patient with a partial response had an almost 100 per cent reduction in tumour size by the end of the study.
“Publication in a peer-reviewed journal means that this paper was rigorously evaluated by independent scientists before being accepted for publication,” said Noxopharm Chief Medical Officer, Dr Gisela Mautner.
“It is heartening to receive this further validation of the science behind Veyonda.”
“Chemotherapy remains the predominant form of cancer drug therapy for most forms of cancer, making the use of Veyonda a highly attractive proposition for boosting both the effectiveness and safety of this major form of cancer management,” said Dr Mautner.
Noxopharm is now in the process of reviewing its clinical programs portfolio for a further study in combination with chemotherapy. The company says a market update will be provided in the near future.
Noxopharm shares are down 1.67 per cent, trading at 59 cents at 1:50 pm AEST.
